Posted by Michael Wonder on 13 Aug 2024
Lenz Therapeutics announces submission of new drug application to US FDA for LNZ100 for the treatment of presbyopia
12 August 2024 - Lenz Therapeutics today announced that the Company has submitted a new drug application to US FDA for LNZ100 (an aceclidine-based ophthalmic solution) for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
The new drug application submission is supported by positive data from the pivotal Phase 3 CLARITY study of LNZ100 for the treatment of presbyopia.
